Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion

被引:16
作者
Embry, Addie [1 ]
Meng, Xiangzhi [1 ]
Cantwell, Angelene [1 ]
Dube, Peter H. [1 ]
Xiang, Yan [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA
关键词
Smallpox; Plague; Vaccinia; Antibody; RECOMBINANT V-ANTIGEN; YERSINIA-PESTIS; PNEUMONIC PLAGUE; MONOCLONAL-ANTIBODIES; SMALLPOX VACCINE; FUSION PROTEIN; HIV-1; ENV; PROTECTION; MICE; EXPRESSION;
D O I
10.1016/j.vaccine.2011.05.088
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccinia virus (VACV) is the vaccine for smallpox and a widely used vaccine vector for infectious diseases and cancers. The majority of the antibodies elicited by live VACV vaccination respond to virion structural proteins, including many integral membrane proteins on the intracellular mature virion (MV). Here, we showed that antibody response to an exogenous antigen delivered by VACV was greatly enhanced by incorporating the antigen as an integral membrane protein of MV. We constructed recombinant VACV expressing a Yersinia pestis protective antigen. LcrV, unmodified or fused with either a signal peptide or with the transmembrane domain of VACV D8 protein (LcrV-TM). Electron microscopy showed that LcrV-TM was displayed on the surface of MV. Importantly, VACV expressing LcrV-TM elicited a significantly higher titer of anti-LcrV antibody in mice than viruses expressing other forms of LcrV. Only mice immunized with LcrV-TM-expressing VACV were protected from lethal Y. pestis and VACV WR challenges. Antigen engineering through fusion with D8 transmembrane domain may be broadly applicable for enhancing the immune response to antigens delivered by a VACV vector. The recombinant virus described here could also serve as the basis for developing a vaccine against both smallpox and plague. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5331 / 5339
页数:9
相关论文
共 51 条
  • [1] Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis
    Anderson, GW
    Worsham, PL
    Bolt, CR
    Andrews, GP
    Welkos, SL
    Friedlander, AM
    Burans, JP
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1997, 56 (04) : 471 - 473
  • [2] EV01:: A phase I trial in healthy HIV negative volunteers to evaluate a clade CHIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium
    Bart, Pierre-Alexandre
    Goodall, Ruth
    Barber, Tristan
    Harari, Alexandre
    Guimaraes-Walker, Ana
    Khonkarly, Mona
    Sheppard, Neil C.
    Bangala, Yolanda
    Frachette, Marie-Joelle
    Wagner, Ralf
    Liljestrom, Peter
    Kraehenbuhl, Jean-Pierre
    Girard, Marc
    Goudsmit, Jaap
    Esteban, Mariano
    Heeney, Jonathan
    Sattentau, Quentin
    McCormack, Sheena
    Babiker, Abdel
    Pantaleo, Giuseppe
    Weber, Jonathan
    [J]. VACCINE, 2008, 26 (25) : 3153 - 3161
  • [3] Development of in vitro correlate assays of immunity to infection with Yersinia pestis
    Bashaw, J.
    Norris, S.
    Weeks, S.
    Trevino, S.
    Adamovicz, J. J.
    Welkos, S.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (05) : 605 - 616
  • [4] A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
    Bejon, Philip
    Mwacharo, Jedidah
    Kai, Oscar
    Mwangi, Tabitha
    Milligan, Paul
    Todryk, Stephen
    Keating, Sheila
    Lang, Trudie
    Lowe, Brett
    Gikonyo, Caroline
    Molyneux, Catherine
    Fegan, Greg
    Gilbert, Sarah C.
    Peshu, Norbert
    Marsh, Kevin
    Hill, Adrian V. S.
    [J]. PLOS CLINICAL TRIALS, 2006, 1 (06):
  • [5] Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis
    Bhattacharya, Debaditya
    Mecsas, Joan
    Hu, Linden T.
    [J]. VACCINE, 2010, 28 (48) : 7683 - 7689
  • [6] Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice
    Brewoo, Joseph N.
    Powell, Tim D.
    Stinchcomb, Dan T.
    Osorio, Jorge E.
    [J]. VACCINE, 2010, 28 (36) : 5891 - 5899
  • [7] Yersinia pestis CO92ΔyopH is a potent live, attenuated plague vaccine
    Bubeck, Sarah S.
    Dube, Peter H.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (09) : 1235 - 1238
  • [8] Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice
    Bubeck, Sarah S.
    Cantwell, Angelene M.
    Dube, Peter H.
    [J]. INFECTION AND IMMUNITY, 2007, 75 (02) : 697 - 705
  • [9] DECREASED VIRULENCE OF RECOMBINANT VACCINIA VIRUS EXPRESSION VECTORS IS ASSOCIATED WITH A THYMIDINE KINASE-NEGATIVE PHENOTYPE
    BULLER, RML
    SMITH, GL
    CREMER, K
    NOTKINS, AL
    MOSS, B
    [J]. NATURE, 1985, 317 (6040) : 813 - 815
  • [10] YopH inhibits early pro-inflammatory cytokine responses during plague pneumonia
    Cantwell, Angelene M.
    Bubeck, Sarah S.
    Dube, Peter H.
    [J]. BMC IMMUNOLOGY, 2010, 11